28th Oct 2005 07:01
GlaxoSmithKline PLC28 October 2005 London, UK - 28th October 2005GlaxoSmithKline plc GlaxoSmithKline plc's Earnings Guidance As announced on 27th October 2005 GSK's earnings guidance for 2005 is 'mid-teens' EPS percentage growth in constant exchange rate (CER) terms. The web cast material accompanying the third quarter results inadvertentlyincluded, for a short period of time, an internal estimate for 2005 EPS of 79.9pand growth of approximately 17 percent in CER terms. This estimate is consistentwith the Company's earnings guidance but is a point estimate in time and subjectto a number of assumptions which are regularly reviewed and can change dependingon business performance and other circumstances. The Company's earnings guidance remains 'mid-teens' EPS percentage growth in CERterms. S M BicknellCompany Secretary 28th October 2005 GlaxoSmithKline - one of the world's leading research-based pharmaceutical andhealthcare companies - is committed to improving the quality of human life byenabling people to do more, feel better and live longer. For company informationvisit www.gsk.com. Enquiries: UK Media Philip Thomson (020) 8047 5502 David Mawdsley (020) 8047 5502 Chris Hunter-Ward (020) 8047 5502 Alice Hunt (020) 8047 5502 US Media Nancy Pekarek (215) 751 7709 Mary Anne Rhyne (919) 483 2839 Patricia Seif (215) 751 7709 European Analyst / Investor Duncan Learmouth (020) 8047 5540 Anita Kidgell (020) 8047 5542 Jen Hill (020) 8047 5543 US Analyst / Investor Frank Murdolo (215) 751 7002 Tom Curry (215) 751 5419 Cautionary statement regarding forward-looking statements Under the safe harbor provisions of the US Private Securities Litigation ReformAct of 1995, the Company cautions investors that any forward-looking statementsor projections made by the Company, including those made in this Announcement,are subject to risks and uncertainties that may cause actual results to differmaterially from those projected. Factors that may affect the Group's operationsare described under 'Risk Factors' in the Operating and Financial Review andProspects in the Company's Annual Report 2004. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Glaxosmithkline